Drug Trial Radar · NCT07883382
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Oct 28, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantation. Treatment will continue through the peri-transplant period and for up to 24 weeks after hematopoietic reconstitution. The primary endpoint is the engraftment rate at day +28 post-transplant. Secondary endpoints include poor graft function rate, grade III-IV acute GVHD rate, overall survival, infection rate, and bone marrow fibrosis grade changes.
Conditions
- Myeloid Neoplasms With Myelofibrosis
Interventions
gecacitinib Hydrochloride TabletsDrug
gecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10\^9/L, or 50 mg BID if platelets \<50×10\^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10\^9/L and ANC ≥0.5×10\^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation. Dose adjustments are made based on adverse events and hematologic parameters, with a maximum dose of 100 mg BID and minimum of 50 mg once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Engraftment Rate at Day +28 Post-TransplantTime frame: Day +28 post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 197, Ruijin Second Road, Shanghai
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.